<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Portal vein embolization (PVE) may increase the resectability of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the problem of PVE is insufficient growth of the liver or <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> in some patients </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to evaluate the significance of commonly available clinical factors for the result of PVE </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIAL AND METHODS: Portal vein embolization was performed in 38 patients with colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Effects of age, gender, time between PVE and liver resection, oncological therapy after PVE, <z:chebi fb="0" ids="31696">indocyanine green</z:chebi> retention rate test, synchronous, metachronous and extrahepatic <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, liver volume before and after PVE, increase of liver volume after PVE and the quality of liver parenchyma before PVE on the result of PVE were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Liver resection was performed in 23 (62.2%) patients within 1.3 Â±0.4 months after PVE </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">Tumor progression</z:e> occurred in 9 (23.7%) patients and 6 (15.8%) patients had insufficient liver <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Significant clinical factors of PVE failure were number of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> (cut-off - 4; odds ratio - 4.7; p &lt; 0.03), liver volume after PVE (cut-off 1000 cm(3); odds ratio - 5.1; p &lt; 0.02), growth of liver volume after PVE (cut-off 150 cm(3); odds ratio - 18.7; p &lt; 0.002), oncological therapy administered concomitantly with PVE (p &lt; 0.003) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Negative clinical factors of resectability of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> after PVE included more than four <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e>, liver volume after PVE &lt; 1000 cm(3), growth of the contralateral lobe by less than 150 cm(3) and concurrent oncological therapy </plain></SENT>
</text></document>